Phase 3 clinical trial of AstraZeneca's Imfinzi (durvalumab) reaches primary and sub-end

Today, AstraZenecacompany(http://announced that its PD-L1 monoclonal antibody Imfinzi (durvalumab) and chemotherapy-based combination therapy, with the addition of anti-CTLA-4 antibodies tre Melimumab's triple combination therapy reached the primary and critical secondary endpoints in phase 3 clinicaltrial
s (http://POSEIDON in patients with stage IV (Stage 4) non-small cell lung cancer (NSCLC)both combination therapies provide statistically significant and clinically significant improvements in patients' progressionless life span (PFS) compared to chemotherapy aloneAbout Imfinzi
Imfinzi is a humanized PD-L1 monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 receptors, thus blocking pD-L1's suppression of the immune responseImfinzi has been approved by theFDA(http://to treat patients with advanced bladder cancer and Patients with NSCLC who cannot be removed from stage 3the study
a randomized, international multicenter Phase 3 clinical trialPatients involved in the trial included scaly and non-scaly expression PD-L1, but did not carry metastatic NSCLC patients with eGFR or ALK gene mutationsThe main endpoints of thetrial were IMFinzi's combination with chemotherapy for PFS and total survival (OS) treatment in Patients of NSCLC, and the secondary endpoints included Imfinzi and tremelimumab and chemotherapy triple therapy for PFS and OS treatment in Patients of NSCLCresults showed that the combination therapy of Imfinzi-plus chemotherapy and the triple therapy of the addition of tremelimumab resulted in a significant improvement in the patient's PFS to the primary and critical secondary ends of the trial, compared to individual chemotherapy